Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection

Megliorino, Roxanne; Shi, Fu Dong; Peng, Xuan; Wang, Xiao; Chan, Edward K. L.; Tan, Eng M.; Zhang, Jian Ying

doi:10.1016/j.cdp.2005.03.002

Cited by 42 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our inability to find survivin autoantibodies in NSCLC patients is not in agreement with the results reported by others (11)(12)(13)(14)(15)(16)(17)(18), who found survivin autoantibodies with an 8% to 52% prevalence. Although these inconsistent findings may have been due to differences in the type of tumor, the stage of lung cancer, or the source of antigen, the most likely explanation is the difference in assay methodology.…”

Section: Discussioncontrasting

confidence: 57%

“…Antibodies to survivin are one of the autoantibodies described most frequently in lung cancer (5,(11)(12)(13)(14)(15)(16)(17)(18). Survivin, also known as baculoviral IAP repeat-containing protein 5 (BIRC5), is a member of the inhibitor apoptosis proteins (IAP) family.…”

Section: Introductionmentioning

confidence: 99%

“…For that purpose, we collected, NSCLC cases from the NELSON trial with well-matched controls to the NSCLC cases, subdivided into individuals who were currently smoking or were former smokers. In addition, we included late-stage NSCLC patients from the Dutch Association of Pulmonologists for Lung Diseases and Tuberculosis (NVALT)-12 study (22) and a control group of generally healthy blood donors, similar to that used in the publications on survivin autoantibodies (5,(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

“…All published studies on survivin autoantibodies in lung cancer have used the direct antigen-coating (DAC) form of an ELISA with a recombinant survivin (5,(11)(12)(13)(14)(15)(16)(17)(18). However, the DAC-ELISA assay can give false-positive results if antibodies bind to impurities in the antigen preparation.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Broodman

VanDuijn

Stingl

et al. 2016

Cancer Immunology Research

View full text Add to dashboard Cite

The high mortality rate in lung cancer is largely attributable to late diagnosis. Case-control studies suggest that autoantibodies to the survivin protein are potential biomarkers for early diagnosis. We tested the hypothesis that sandwich ELISA can detect autoantibodies to survivin before radiologic diagnosis in patients with early-stage non-small cell lung cancer (NSCLC). Because previous studies assayed survivin autoantibodies with the direct antigencoating ELISA (DAC-ELISA), we first compared that assay with the sandwich ELISA. Based on the more robust results from the sandwich ELISA, we used it to measure survivin autoantibodies in the serum of 100 individuals from a well-controlled population study [the Dutch-Belgian Lung Cancer Screening Trial (NELSON) trial] composed of current and former smokers (50 patients with NSCLC, both before and after diagnosis, and 50 matched, smoking-habit control subjects), and another 50 healthy nonsmoking control subjects. We found no difference in specific autoantibodies to survivin in NSCLC patients, although nonspecific median optical densities were 24% higher (P < 0.001) in both NSCLC patients and smokers, than in healthy nonsmokers. Finally, we confirmed the ELISA results with Western blot analysis of recombinant and endogenous survivin (HEK-293), which showed no anti-survivin reactivity in patient sera. We conclude that specific anti-survivin autoantibody reactivity is most likely not present in sera before or after diagnosis. Autoantibody studies benefit from a comparison to a well-controlled population, stratified for smoking habit.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Broodman

VanDuijn

Stingl

et al. 2016

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…Furthermore, survivin expression is known to participate in the grade, metastasis and aggressiveness of human tumors [3,4]. Whether survivin found extracellularly originates from dead cancer cells or is actively secreted is presently unknown, although survivin has been demonstrated to induce antibody responses in human cancer patients and might be a useful tumor marker [6,10,11]. In addition, survivin overexpression might be associated with the malignancy of mast cell tumors, lymphoma and carcinoma in dogs [7][8][9].…”

mentioning

confidence: 99%

Detection of Autoantibodies against Survivin in Sera from Cancer Dogs

Tango

Kano

Maruyama

et al. 2010

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Survivin overexpression has been reported in relation to tumor malignancy, suggesting that it is an unfavorable prognostic marker, and antibody responses to this protein have been confirmed in human cancer patients. In this study, we investigated antibody responses to survivin in canine cancer cases, and examined the prevalence of such responses by enzyme-linked immunosorbent assay (ELISA) using recombinant canine survivin protein as the antigen. The cut-off value for positivity in the anti-survivin ELISA was 0.35, as determined using the mean absorbance +2 S.D. of samples from healthy dogs. Sera from 16 of 59 (27.1%) cancer and 3 of 25 (12%) non-cancer disease dogs were positive on ELISA. The highest positivity rates (>50%) among the cancer cases were seen in dogs with mammary tumor, squamous cell carcinoma and melanoma.

show abstract

Antibody responses to survivin and their clinical significance in patients with head and neck cancer

Eto¹,

Kodama²,

Uemura³

et al. 2007

Head & Neck

View full text Add to dashboard Cite

show abstract

Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection

Cited by 42 publications

References 26 publications

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Detection of Autoantibodies against Survivin in Sera from Cancer Dogs

Antibody responses to survivin and their clinical significance in patients with head and neck cancer

Contact Info

Product

Resources

About